Comparison · NCT00000620-a3935b02
Lipid Trial: Fenofibrate vs Lipid Trial: Placebo: First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial.
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Lipid Trial: Fenofibrate vs Lipid Trial: Placebo: First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial. Trial comparisons, record NCT00000620-a3935b02. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00000620-a3935b02
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.232 | 0.216 | 0.248 | wilson | |
| Risk in group 2 | 0.242 | 0.227 | 0.259 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0105 | -0.0329 | 0.012 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.957 | 0.87 | 1.05 | log | |
| Odds ratio, group 1 over group 2 | 0.944 | 0.834 | 1.07 | log | |
| Number needed to treat, for one fewer participant with the outcome on Lipid Trial: Fenofibrate than on Lipid Trial: Placebo | 95.7 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Lipid Trial: Fenofibrate | Double blind administration of 160 mg/day of fenofibrate in participants with estimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73m\^2 or 54 mg/day in patients with eGFR \<50 mL/min/1.73m\^2, in combination with open label simvastatin 20 - 40 mg/day. | 641 | 2,765 | OG000 |
| Group 2 | Lipid Trial: Placebo | Double blind administration of placebo matching either 160 mg/day in participants with eGFR ≥50 mL/min/1.73m\^2 or 54 mg/day in participants with eGFR \<50 mL/min/1.73m\^2, in combination with open label simvastatin 20 - 40 mg/day. | 667 | 2,753 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial.
- Description
- Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, cardiovascular death, revascularization procedure or hospitalization for CHF in Lipid Trial participants.
- Time frame
- 4.7 years
- Population
- The population analyzed included all participants randomized and was performed by intention to treat with right-censoring of participants who did not complete follow-up prior occurrence of event.
Source ClinicalTrials.gov
Trial
- Title
- Action to Control Cardiovascular Risk in Diabetes (ACCORD)
- NCT number
- NCT00000620
- Phases
- PHASE3
- Conditions
- Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Type 2, Diabetes Mellitus, Coronary Disease
- Interventions
- Anti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- Results first posted
- 2014-09-15
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00000620?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00000620-a3935b02